Five major categories of CLD were considered: alcohol-related liver disease (ALD), chronic hepatitis B (CH-B), chronic hepatitis C (CH-C), NAFLD, and iron overload (defined at the transferrin saturation level of 50% or higher). Alcohol-related liver disease was presumed in subjects who reported excessive

alcohol consumption and had elevated serum aminotransferases (both defined in Table 1). CH-B was defined as being positive for HBsAg, regardless of the anti-HBc or anti-HBs status. It is important to note that the length time for HBsAg-positivity was not available in the NHANES data collection, so we could not reliably distinguish between those with recent and chronic HepB infection. Furthermore, individuals with positive serology for anti-HCV were defined as hepatitis C antibody positive (HCV+). Of the HCV+ patients with available BMN673 data, approximately 75% were selleck chemical HCV RNA positive and were considered to have CH-C. Finally, subjects were presumed to have NAFLD if they had elevated serum aminotransferases in the absence of any other evidence of CLD, such as alcohol use, iron overload, or a positive hepatitis B or hepatitis C serologic

test. Together, individuals with ALD, CH-B, HCV, iron overload, and NAFLD were included in the cohort of CLD. Subjects without evidence of CLD, according to the inclusion criteria described here, were considered to have no CLD and were used as controls. Given the lack of additional iron studies needed to establish the diagnosis of hemochromatosis, we elected not to study iron overload separately. Because NHANES does not collect information on the date of diagnosis for diabetes, we were unable to distinguish between type I and II diabetes. However, because we have limited our assessment of diabetes to adults only, we believe that these patients with diabetes mostly have type II diabetes. A self-reported history of receiving hepatitis A and B vaccinations was collected from the NHANES Immunization questionnaires. Vaccination against hepatitis A (or hepatitis B) was defined as receiving at least one dose

of the vaccine. If fewer than two doses of HepA vaccine (fewer than three for HepB vaccine) were reported, the series MCE公司 was presumed incomplete. Effective vaccination was defined as any number of doses of HepA (or HepB) vaccine and positive anti-HAV (positive anti-HBs without anti-HBc). The quality measure (QM) for HepA vaccination (or HepB vaccination) was defined for all study participants using the Medicare definition for QM for patients with hepatitis C: “percentage of individuals aged 18 years and older with a diagnosis of hepatitis C who received at least one injection of hepatitis A (or B) vaccine, or who had documented immunity to hepatitis A (or B)”.39, 40 When defining QM, in addition to anti-HBs immunity, natural immunity for hepatitis B was defined as positive anti-HBc (regardless of anti-HBs) in the absence of HBsAg.